Dataset Information

Cγ and lupanine enhances in vivo the antidiabetic effect and involves modulation of the liver gene expression profile

ABSTRACT: Previous studies have individually shown the antidiabetic potential of gamma conglutin (Cγ) and lupanine from lupins. Until now, the influence of combines both compounds and the effective dose of the combination is not assessed. Moreover, the resulting gene profile from this novel combination remains to be explored. Therefore, we proposed to study different dose combinations of Cγ and lupanine by the oral glucose tolerance test (OGTT) to identify the greater antidiabetic effect on the T2D rat model. Later, we administered the selected dose combination for a week. Finally, we evaluated the gene expression profile using DNA microarrays and its bioinformatic analysis. We found that the combination of 28 mg/kg BW Cγ + 20 mg/kg BW lupanine positively influences the expression of Pdk4, Ppargc1a, Foxo1, and Foxo3 genes. The reestablishment of Pdk4 gene expression is involved in several biological processes associated with regulation, metabolism, and homeostasis of glucose and fatty acids. For the first time, we reported the beneficial effect of the combination of two functional lupin compounds in a T2D rat model. Nevertheless, further studies are needed to investigate the pharmacokinetics and pharmacodynamics of the Cγ + lupanine combination. Gene expression analysis of RNA samples from liver tissue of healthy and diabetic-induced rats.

ORGANISM(S): Rattus norvegicus

PROVIDER: GSE216668 | GEO | 2023/01/25

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:The objective of this study was to determine the therapeutic effect and PK/PD relationship of Hibercell compound HC-7366 after 3 days continuous BID dosing (7 administrations) in the MOLM-16 subcutaneous leukemia xenograft model. Single point plasma concentrations were determined 1 h post dose on day 4. HC-7366 at dose levels of 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg and 30 mg/kg BID dosing all exhibited significant antitumor activities with TGI% values of 74.8%, 91.5%, 93.6%, 82.0%, and 62.0% (P values < 0.05 vs. vehicle control group), respectively. The maximum antitumor effects were achieved at 3 mg/kg which resulted in Partial Response (PR, ≥50% tumor regression) in 100% of animals. The plasma concentrations of HC-7366 at 1 h post dose on day 4 provided a single point determination of systemic exposure. The concentrations increased in approximate proportion to dose level across the range 0.3 – 30 mg/kg. These data indicate that HC-7366 treatment exhibits a ‘U-shaped’ dose/exposure-response relationship in this model when dosed at 0.3, 1, 3, 10 or 30 mg/kg, orally (PO), twice per day (BID). Regarding the safety profile, most animals treated with HC-7366 at dose level of 1 mg/kg and 3 mg/kg showed minor to moderate BW loss during the study period. IHC on these samples demonstrated maximal induction of the ATF4 targets ASNS, PSAT1 and PHGDH at 1 and 3 mg/kg doses, with 0.3, 10 and 30 have smaller increases over vehicle. RNA-Seq confirmed that the ASNS, PSAT1 and PHGDH effects were regulated at the mRNA level in the U-shaped manner. DDIT3, BBC3, and ATF4 mRNA also demonstrated a U-shaped upregulation, with maximal effect at 3 mg/kg. Notably, PPP1R15A, MCL1, PPP1R15B, EIF2AK4, CASP3, and EIF2S1 mRNA showed much more modest regulation. These data strongly suggest that HC-7366 is having its maximal efficacy in MOLM-16 when it is behaving as a GCN2 activator (i.e., at 1 and 3 mg/kg), where higher concentrations begin to inhibit this effect (at 10 and 30 mg/kg).

Dataset Information

Cγ and lupanine enhances in vivo the antidiabetic effect and involves modulation of the liver gene expression profile

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets